株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

潰瘍性大腸炎市場・予測分析

Ulcerative Colitis Market and Forecast Analysis

発行 Datamonitor Healthcare 商品コード 498957
出版日 ページ情報 英文 282 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
潰瘍性大腸炎市場・予測分析 Ulcerative Colitis Market and Forecast Analysis
出版日: 2017年03月02日 ページ情報: 英文 282 Pages
概要

米国、日本、EU5カ国 (フランス、ドイツ、イタリア、スペイン、英国) における潰瘍性大腸炎の診断患者数は2015年から2035年にかけて16.6%増加し、2015年の210万人から、250万人に増加すると予測されています。

当レポートでは、潰瘍性大腸炎の上市済み薬剤およびパイプラインの動向を調査し、疾患の概要、現在の治療オプション、処方動向、アンメットニーズ、地域/国別の診断患者数の推移と予測、主な上市済み薬剤のプロファイル、パイプラインの動向などをまとめています。

治療:潰瘍性大腸炎

  • エグゼクティブサマリー
  • 主要調査手法
  • 患者区分
  • 国別治療ツリー:クローン病
  • 国別治療ツリー:潰瘍性大腸炎
  • 現在の治療オプション
  • 処方動向:クローン病
  • 処方動向:潰瘍性大腸炎
  • 処方への影響因子
  • 炎症性腸疾患のアンメットニーズ

疫学:潰瘍性大腸炎

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報ソース・調査手法
  • 予測
  • 疫学者の考察
  • 強み・制約
  • 付録

上市済み薬剤:潰瘍性大腸炎

  • エグゼクティブサマリー
  • 製品概要
  • 製品プロファイル:Apriso
  • 製品プロファイル:Delzicol/Asacol HD
  • 製品プロファイル:Entyvio
  • 製品プロファイル:Humira
  • 製品プロファイル:Lialda
  • 製品プロファイル:Pentasa
  • 製品プロファイル:Remicade
  • 製品プロファイル:Simponi
  • 製品プロファイル:Uceris

パイプライン:潰瘍性大腸炎

  • エグゼクティブサマリー
  • 臨床パイプライン:概要
  • 対象製品プロファイル
  • 製品プロファイル (後期):LT-02
  • 製品プロファイル (後期):Xeljanz
  • 製品プロファイル (後期):etrolizumab

図表

目次
Product Code: DMKC5435

Disease Overview

Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost layer of the intestinal lining. Ulcerative colitis is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Ulcerative colitis is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet. Incidence and prevalence have been increasing over the past two decades in most regions of the world.

Datamonitor Healthcare estimates that in 2015, there were 2.1 million diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015-35, the number of prevalent cases is expected to increase to 2.5 million (16.6% increase).

TABLE OF CONTENTS

TREATMENT: ULCERATIVE COLITIS

  • Executive Summary
  • Primary Research Methodology
  • Patient Segmentation
  • Country Treatment Trees: Crohn's Disease
  • Country Treatment Trees: Ulcerative Colitis
  • Current Treatment Options
  • Prescribing Trends: Crohn's Disease
  • Prescribing Trends: Ulcerative Colitis
  • Prescribing Influences
  • Unmet Needs in Inflammatory Bowel Disease

EPIDEMIOLOGY: ULCERATIVE COLITIS

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix

MARKETED DRUGS: ULCERATIVE COLITIS

  • Executive Summary
  • Product Overview
  • Product profile: Apriso
  • Product profile: Delzicol/Asacol HD
  • Product profile: Entyvio
  • Product profile: Humira
  • Product profile: Lialda
  • Product profile: Pentasa
  • Product profile: Remicade
  • Product profile: Simponi
  • Product profile: Uceris

PIPELINE: ULCERATIVE COLITIS

  • Executive Summary
  • Clinical Pipeline Overview
  • Target Product Profile
  • Product profile (late stage): LT-02
  • Product profile (late stage): Xeljanz
  • Product profile (late stage): etrolizumab

APPENDIX

  • Appendix: Marketed Drugs: Ulcerative Colitis
  • Appendix: Pipeline: Ulcerative Colitis

LIST OF FIGURES

  • Figure 1: US Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 2: Japan Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 3: France Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 4: Germany Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 5: Italy Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 6: Spain Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 7: UK Crohn's disease diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 8: US ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 9: Japan ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 10: France ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 11: Germany ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 12: Italy ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 13: Spain ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 14: UK ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
  • Figure 15: Mean percentage of Crohn's disease and ulcerative colitis patients who receive pharmacological therapy, by country
  • Figure 16: Mean percentage use of Crohn's disease drug classes in the US, Japan, and five major EU markets, by line of therapy
  • Figure 17: Mean percentage of drug-treated Crohn's disease patients treated with monotherapy versus combination therapy, by line of therapy
  • Figure 18: Mean percentage use of biologics for drug-treated Crohn's disease patients, by country and line of therapy
  • Figure 19: Mean percentage use of biologic brands for the treatment of drug-treated Crohn's disease patients, by line of therapy
  • Figure 20: Mean compliance rates for drug-treated Crohn's disease patients, by formulation
  • Figure 21: Mean percentage use of ulcerative colitis drug classes in the US, Japan, and five major EU markets, by line of therapy
  • Figure 22: Mean percentage of drug-treated ulcerative colitis patients treated with monotherapy versus combination therapy, by line of therapy
  • Figure 23: Mean percentage use of biologics for drug-treated ulcerative colitis patients, by country and line of therapy
  • Figure 24: Mean percentage use of biologic brands for the treatment of drug-treated ulcerative colitis patients, by line of therapy
  • Figure 25: Mean compliance rates for drug-treated ulcerative colitis patients, by formulation
  • Figure 26: Mean percentage of Crohn's disease patients treated by each type of healthcare professional
  • Figure 27: Mean percentage of ulcerative colitis patients treated by each type of healthcare professional
  • Figure 28: Top factors that influence the prescribing of biologics and aminosalicylates for inflammatory bowel disease patients
  • Figure 29: Treatment challenges in Crohn's disease
  • Figure 30: Treatment challenges in ulcerative colitis
  • Figure 31: Trends in diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 32: Absolute growth of diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 33: Male diagnosed prevalent ulcerative colitis cases in each age group in the US, Japan, and five major EU markets, by country, 2015
  • Figure 34: Female diagnosed prevalent ulcerative colitis cases in each age group in the US, Japan, and five major EU markets, by country, 2015
  • Figure 35: Apriso for ulcerative colitis - SWOT analysis
  • Figure 36: Datamonitor Healthcare drug assessment of Apriso in ulcerative colitis
  • Figure 37: Datamonitor Healthcare drug assessment of Apriso in ulcerative colitis
  • Figure 38: Delzicol and Asacol HD for ulcerative colitis - SWOT analysis
  • Figure 39: Datamonitor Healthcare drug assessment of Delzicol (Asacol)/Asacol HD in ulcerative colitis
  • Figure 40: Datamonitor Healthcare drug assessment of Delzicol (Asacol)/Asacol HD in ulcerative colitis
  • Figure 41: Entyvio for ulcerative colitis - SWOT analysis
  • Figure 42: Datamonitor Healthcare drug assessment of Entyvio in ulcerative colitis
  • Figure 43: Datamonitor Healthcare drug assessment of Entyvio in ulcerative colitis
  • Figure 44: Humira for ulcerative colitis - SWOT analysis
  • Figure 45: Datamonitor Healthcare drug assessment of Humira in ulcerative colitis
  • Figure 46: Datamonitor Healthcare drug assessment of Humira in ulcerative colitis
  • Figure 47: Lialda for ulcerative colitis - SWOT analysis
  • Figure 48: Datamonitor Healthcare drug assessment of Lialda in ulcerative colitis
  • Figure 49: Datamonitor Healthcare drug assessment of Lialda in ulcerative colitis
  • Figure 50: Pentasa for ulcerative colitis - SWOT analysis
  • Figure 51: Datamonitor Healthcare drug assessment of Pentasa in ulcerative colitis
  • Figure 52: Datamonitor Healthcare drug assessment of Pentasa in ulcerative colitis
  • Figure 53: Remicade for ulcerative colitis - SWOT analysis
  • Figure 54: Datamonitor Healthcare drug assessment of Remicade in ulcerative colitis
  • Figure 55: Datamonitor Healthcare drug assessment of Remicade in ulcerative colitis
  • Figure 56: Simponi for ulcerative colitis - SWOT analysis
  • Figure 57: Datamonitor Healthcare drug assessment of Simponi in ulcerative colitis
  • Figure 58: Datamonitor Healthcare drug assessment of Simponi in ulcerative colitis
  • Figure 59: Uceris SWOT analysis in ulcerative colitis
  • Figure 60: Datamonitor Healthcare drug assessment of Uceris in ulcerative colitis
  • Figure 61: Datamonitor Healthcare drug assessment of Uceris in ulcerative colitis

LIST OF TABLES

  • Figure 62: LT-02 for ulcerative colitis - SWOT analysis
  • Figure 63: Datamonitor Healthcare drug assessment of LT-02 in ulcerative colitis
  • Figure 64: Datamonitor Healthcare drug assessment of LT-02 in ulcerative colitis
  • Figure 65: Results from Phase II trial of Xeljanz in ulcerative colitis
  • Figure 66: Xeljanz for ulcerative colitis - SWOT analysis
  • Figure 67: Datamonitor Healthcare drug assessment of Xeljanz in ulcerative colitis
  • Figure 68: Datamonitor Healthcare drug assessment of Xeljanz in ulcerative colitis
  • Figure 69: Etrolizumab for ulcerative colitis - SWOT analysis
  • Figure 70: Datamonitor Healthcare drug assessment of etrolizumab in ulcerative colitis
  • Figure 71: Datamonitor Healthcare drug assessment of etrolizumab in ulcerative colitis
  • Table 1: Gastroenterologists surveyed for the inflammatory bowel disease primary research study
  • Table 2: Definition of mild, moderate, and severe Crohn's disease
  • Table 3: Definition of mild, moderate, and severe ulcerative colitis
  • Table 4: Drug classes used in the treatment of inflammatory bowel disease
  • Table 5: Treatment guidelines: initial treatment for active Crohn's disease, by severity
  • Table 6: Treatment guidelines: maintenance of medically induced remission of Crohn's disease and other therapy recommendations
  • Table 7: Treatment guidelines: initial treatment for active ulcerative colitis, by severity
  • Table 8: Treatment guidelines: maintenance of medically induced remission of ulcerative colitis and other therapy recommendations
  • Table 9: Mean percentage of drug-treated Crohn's disease patients treated with monotherapy versus combination therapy, by line of therapy and country
  • Table 10: Mean percentage of drug-treated Crohn's disease patients receiving each biologic, by country and line of therapy
  • Table 11: Mean percentage of drug-treated ulcerative colitis patients treated with monotherapy versus combination therapy, by line of therapy and country
  • Table 12: Mean percentage of drug-treated ulcerative colitis patients receiving each biologic, by country and line of therapy
  • Table 13: Factors influencing prescription of biologics and aminosalicylates for inflammatory bowel disease, by country
  • Table 14: Mean ranking given to each clinical unmet need in the treatment of Crohn's disease, by country
  • Table 15: Mean ranking given to each clinical unmet need in the treatment of ulcerative colitis, by country
  • Table 16: Inflammatory bowel disease risk factors
  • Table 17: Sources used for ulcerative colitis analysis in the US, Japan, and five major EU markets
  • Table 18: Notable sources not used for ulcerative colitis analysis in the US, Japan, and five major EU markets
  • Table 19: Summary of ulcerative colitis data processing in the US, Japan, and five major EU markets
  • Table 20: Diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 21: Age- and gender-specific diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015
  • Table 22: Phenotypic distribution of ulcerative colitis at diagnosis, by Montreal classification and country, 2015
  • Table 23: Key marketed drugs for ulcerative colitis
  • Table 24: Apriso drug profile
  • Table 25: Overview of pivotal trial data for Apriso in ulcerative colitis
  • Table 26: Delzicol/Asacol HD drug profile
  • Table 27: Overview of pivotal trial data for Asacol and Asacol HD in ulcerative colitis
  • Table 28: Entyvio drug profile
  • Table 29: Overview of pivotal trial data for Entyvio in ulcerative colitis
  • Table 30: Overview of Entyvio ulcerative colitis trial in Japan
  • Table 31: Ongoing long-term clinical trial of Entyvio in Crohn's disease and ulcerative colitis
  • Table 32: Humira drug profile
  • Table 33: Pivotal trial data that led to Humira's approvals for Crohn's disease and ulcerative colitis
  • Table 34: Ongoing clinical trial of Humira in ulcerative colitis
  • Table 35: Lialda drug profile
  • Table 36: Overview of pivotal trial data for Lialda in ulcerative colitis
  • Table 37: Other key clinical trial data for Lialda in ulcerative colitis
  • Table 38: Ongoing clinical trials of Lialda in ulcerative colitis
  • Table 39: Pentasa drug profile
  • Table 40: Overview of pivotal trial data for Pentasa in ulcerative colitis
  • Table 41: Remicade drug profile
  • Table 42: Overview of pivotal trial data for Remicade in ulcerative colitis
  • Table 43: Simponi drug profile
  • Table 44: Overview of pivotal trial data for Simponi in ulcerative colitis
  • Table 45: Overview of Simponi Phase III trial for ulcerative colitis in Japanese patients
  • Table 46: Uceris drug profile
  • Table 47: Overview of pivotal trial data for Uceris in ulcerative colitis
  • Table 48: Phase III data for Uceris/mesalamine combination therapy in ulcerative colitis
  • Table 49: Ongoing Phase III trial of Uceris in Japanese ulcerative colitis patients
  • Table 50: Phase III pipeline candidates under development for ulcerative colitis
  • Table 51: Remicade drug profile
  • Table 52: Ability of comparator therapy Remicade to meet unmet needs in ulcerative colitis
  • Table 53: LT-02 drug profile
  • Table 54: Ongoing pivotal trials of LT-02 in ulcerative colitis
  • Table 55: Results of the Phase II trial of LT-02 in ulcerative colitis
  • Table 56: Xeljanz drug profile
  • Table 57: Ongoing pivotal trials of Xeljanz in ulcerative colitis
  • Table 58: Etrolizumab drug profile
  • Table 59: Ongoing pivotal trials of etrolizumab in ulcerative colitis
  • Table 60: Results of the Phase II EUCALYPTUS trial of etrolizumab in ulcerative colitis
Back to Top